Tony Coles, Cerevel CEO
August 12, 2022 09:11 AM EDTUpdated 09:25 AM
Financing
Bioregnum

Cerev­el's Tony Coles is still count­ing his mon­ey as a ri­val's boost helps fu­el a po­ten­tial $609M wind­fall

These days in biotech, you nev­er want to miss a chance to raise mon­ey for pub­lic com­pa­nies. As much mon­ey as pos­si­ble.

That sur­vival strat­e­gy …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Bris­tol My­ers bets $1.5B on BioN­Tech's PD-L1xVEGF from Bio­theus

Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

Ve­ra posts pos­i­tive Phase 3 rare kid­ney dis­ease da­ta, but crowd­ed mar­ket looms

In race with Merus, Bicara makes the case for two-year sur­vival da­ta

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times